Not everyone thinks LRRK2 is such a big deal."Over the last 20...

Not everyone thinks LRRK2 is such a big deal.

"Over the last 20 years, scientists have discoveredthat changes in a handful of genes can causeinherited forms of Parkinson’s – but these are veryrare. These genes include PINK1, Parkin, LRRK2and GBA1. Variations in these genes may be linkedto Parkinson’s in around 5% of people. We callthese genes ‘risk genes’ because changes in themincrease the risk of Parkinson’s, but not everyonewith these changes will go on to developthe condition."

https://www.imperial.ac.uk/media/imperial-college/medicine/multiple-sclerosis-and-parkinsons-brain-bank/Progress-Issue-17.pdf

This has been posted about before:

[Denali Therapeutics stock climbed 11 percent after the release of positive data from its Phase I clinical trial of DNL201 in Parkinson’s disease.Denali announced positive results from its dose-ranging Phase I clinical trial of DNL201 in Parkinson’s disease. It was a randomized, double-blind, placebo-controlled, oral dose trial in healthy patients. It met all safety, pharmacokinetic, and pharmacodynamic goals. The drug was generally well tolerated with no serious side effects.The drug is a small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2). LRRK2 gene mutations are the most observed genetic cause of Parkinson’s disease and a major cause of lysosomal dysfunction. This adds to the formation of Lewy body protein aggregates and neurodegeneration seen in the disease.LRRK2 regulates lysosomal genesis and function, which doesn’t function properly in Parkinson’s. It may be fixed by inhibiting LRRK2.]

https://www.biospace.com/article/denali-shares-pop-after-positive-parkinson-s-trial-data/

Nice to know a price pop can happen after a successful dose ranging trial, like Prana is doing now. Hope for holders the same rules apply to Prana.